Vericel Gains FDA Approval for MACI Production at New Burlington Facility
Vericel secured FDA approval to commence commercial manufacture of its MACI therapy at a new state-of-the-art facility in Burlington, Massachusetts, beginning in the second quarter of 2026. This expansion increases production capacity to satisfy growing knee cartilage repair demand and opens pathways for MACI commercialization outside the United States.
1. FDA Approval Details
The FDA has approved commercial manufacturing of MACI at Vericel’s new Burlington, Massachusetts facility, authorizing production to begin in the second quarter of 2026. This regulatory milestone validates the facility’s compliance with all necessary quality and safety standards for advanced cell therapy production.
2. Capacity and Production Ramp-Up
The state-of-the-art design significantly expands manufacturing throughput, enabling Vericel to align output with rising demand for restorative knee cartilage repair treatments. The company plans a phased production ramp-up throughout 2026 to optimize supply chain efficiency and meet clinical and commercial requirements.
3. International Commercialization Prospects
Leveraging U.S. approval, Vericel will pursue regulatory submissions in key global markets to facilitate MACI launches in Europe, Asia, and beyond. Successful international approvals could unlock new revenue streams and broaden patient access to its advanced cartilage repair therapy.